Want to see SYRE full AI Analyst Report?
Spyre Therapeutics (SYRE) AI Stock Analysis
Spyre Therapeutics
(NASDAQ:SYRE)
The score is supported primarily by a very strong, debt-free balance sheet and positive clinical/pipeline updates plus fresh financing that extends runway. Offsetting these positives are large ongoing losses and heavy cash burn, alongside weak technical momentum (price below key moving averages and negative MACD). Valuation is constrained by negative earnings and no dividend support.
Spyre Therapeutics (SYRE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $8.91B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.21M
- Price to Earnings (P/E)
- -49.5
- Beta (1Y)
- 1.91
- Revenue Growth
- ―
- EPS Growth
- 28.51%
- Country
- US
- Employees
- 125
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Spyre Therapeutics Business Overview & Revenue Model
Company Description
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclo...
How the Company Makes Money
Spyre Therapeutics is a clinical-stage biotech company, and its ability to generate recurring product revenue depends on successfully developing and commercializing approved therapeutics. As of the latest publicly available information, the company d...
Spyre Therapeutics Financial Statement Overview
Summary
Balance sheet strength (no debt and ~$1.10B equity) supports development runway, but operating performance remains weak with deeply negative TTM net income (~-$178.9M) and significant ongoing cash burn (TTM operating and free cash flow ~-$208.9M). Recent TTM revenue (~$90.5M) is a positive step, but profitability and cash self-funding are not yet demonstrated.
Income Statement
18Very NegativeBalance Sheet
78PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.49M | 0 | 0 | 886.00K | 2.33M | 18.74M |
| Gross Profit | 0 | -171.65M | 0 | 886.00K | 2.33M | 18.74M |
| EBITDA | -185.55M | -209.56M | -207.97M | -127.82M | -81.99M | -64.08M |
| Net Income | -178.92M | -155.20M | -208.02M | -338.79M | -83.81M | -65.80M |
Balance Sheet | ||||||
| Total Assets | 1.17B | 777.78M | 608.48M | 341.86M | 71.14M | 109.93M |
| Cash, Cash Equivalents and Short-Term Investments | 1.15B | 756.53M | 603.09M | 339.28M | 55.71M | 93.13M |
| Total Debt | 0 | 0 | 0 | 0 | 4.63M | 5.06M |
| Total Liabilities | 71.86M | 62.55M | 90.68M | 157.84M | 20.84M | 25.98M |
| Stockholders Equity | 1.10B | 715.24M | 517.80M | 184.02M | 50.30M | 83.94M |
Cash Flow | ||||||
| Free Cash Flow | -208.94M | -169.25M | -157.41M | -99.91M | -80.18M | -54.29M |
| Operating Cash Flow | -208.94M | -169.25M | -157.41M | -99.91M | -80.14M | -53.72M |
| Investing Cash Flow | -463.74M | -143.47M | -353.29M | -108.39M | 57.01M | -22.62M |
| Financing Cash Flow | 753.03M | 309.02M | 410.91M | 361.08M | 42.68M | 1.39M |
Spyre Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRE, the sentiment is Positive. The current price of 96.56 is above the 20-day moving average (MA) of 88.16, above the 50-day MA of 90.06, and above the 200-day MA of 73.22, indicating a bullish trend. The MACD of 2.43 indicates Negative momentum. The RSI at 59.06 is Neutral, neither overbought nor oversold. The STOCH value of 88.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRE.
Spyre Therapeutics Risk Analysis
Spyre Therapeutics disclosed 73 risk factors in its most recent earnings report. Spyre Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksSpyre Therapeutics Peers Comparison
Overall Rating
- SYRE54Neutral
IMVT52Neutral
ORKA50Neutral
ABVX44Neutral
ZBIO44Neutral
MLTX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SYRE | 54Neutral | $8.91B | -49.52 | -24.32% | ― | ― | 28.51% |
| IMVT | 52Neutral | $6.03B | -10.34 | -69.59% | ― | ― | 1.28% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ORKA | 50Neutral | $6.41B | -39.22 | -20.76% | ― | ― | 32.27% |
| ABVX | 44Neutral | $7.76B | -16.78 | -85.88% | ― | ― | ― |
| ZBIO | 44Neutral | $1.85B | -2.95 | -189.68% | ― | -93.33% | -127.13% |
| MLTX | 39Underperform | $1.00B | -3.06 | -82.68% | ― | ― | -37.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc | 96.56 | 72.78 | 306.06% | |
| ORKA | Oruka Therapeutics, Inc. | 96.87 | 70.68 | 269.87% | |
| IMVT | Immunovant, Inc. | 29.17 | 5.39 | 22.67% | |
| MLTX | Moonlake Immunotherapeutics | 11.78 | 1.58 | 15.49% | |
| ABVX | Abivax SA Sponsored ADR | 86.59 | -12.26 | -12.40% | |
| ZBIO | Zenas BioPharma, Inc. | 28.39 | -2.94 | -9.38% |
Spyre Therapeutics Corporate Events
Spyre Therapeutics Announces Major Equity Financing Agreement
PositiveOn October 5, 2026, Spyre Therapeutics entered into an underwriting agreement with a syndicate of investment banks to offer 4,117,648 shares of common stock at $85.00 per share, with a 30-day option for underwriters to buy up to an additional 617,647...
Spyre Therapeutics Reports Positive Phase 2 SKYLINE Data
PositiveOn September 8, 2026, Spyre Therapeutics reported positive 12-week induction topline data from Part A of its Phase 2 SKYLINE trial, evaluating SPY003, an extended half-life anti-IL-23 antibody for moderately-to-severely active ulcerative colitis. SPY...
Spyre Therapeutics reports Phase 2 TL1A trial results
PositiveOn August 25, 2026, Spyre Therapeutics reported topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072, showing both tested doses achieved statistically significant benefits versus placebo o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 07, 2026